NEW YORK (GenomeWeb News) – Myriad Genetics reported after the close of the market Monday that its Fiscal Year 2013 first-quarter revenues increased 21 percent year over year.
The firm also upped its revenue and profit guidance for the year.
The Salt Lake City-based molecular diagnostics firm reported total revenues of $133.4 million for the three months ended Sept. 30, compared to $110.5 million for the first quarter of FY 2012. It beat analysts' consensus estimate of $129.5 million.